Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | PTAFR | P25105 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921931 | 1.00 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1PTAFROPRL1 | |
| SCHEMBL2482970 | 1.00 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1PTAFROPRL1 | |
| SCHEMBL2486793 | 1.00 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1PTAFROPRL1 | |
| SCHEMBL2486154 | 0.90 | TACR1 (0.56) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2489420 | 0.90 | TACR1 (0.56) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2486156 | 0.90 | TACR1 (0.56) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2486681 | 0.89 | TACR1 (0.55) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2486680 | 0.89 | TACR1 (0.55) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2488000 | 0.89 | TACR1 (0.57) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL2487374 | 0.89 | TACR1 (0.57) | TACR1CYP3A4SIGMAR1PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | claimed |
| EP-1921064-B1 | Pharmaceutical composition | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | claimed |
| US-20100081667-A1 | Chemical Compounds | ALVARO GIUSEPPE | 2010-04-01 | — | — | US | claimed |
| US-7648990-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2010-01-19 | — | — | US | claimed |
| EP-2079470-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | Glaxo Group Limited (GB) | 2009-07-22 | — | — | EP | claimed |
| EP-1921064-A1 | Pharmaceutical composition | GLAXO GROUP LIMITED (GB) | 2008-05-14 | — | — | EP | claimed |
| WO-2008046882-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| US-20080021041-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | claimed |
| US-7294630-B2 | Piperazinyl piperidine tachykinin antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | claimed |
| EP-1824487-A1 | THE USE OF 4-(S)-(4-ACETYL-PIPERAZIN-1-YL)-2-(R)-(4-FLUORO-2-METHYL-PHENYL)-PIPERIDINE-1-CARBOXILIC ACID, [1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYLAMIDE FOR THE TREATMENT OF OVERACTIVE BLADDER | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | claimed |
| EP-1653956-A1 | COMBINATIONS OF PAROXETINE AND 4-(S)-(4-ACETYL-PIPERAZIN-1-YL)-2-(R)-(4-FLUORO-2-METHYL-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID ¬1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL|METHYLAMIDE FOR TREATMENT OF DEPRESSION AND/OR ANXIETY. | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | claimed |
| CN-1231468-C | Chemical compounds | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | CN | claimed |
| US-20050137208-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2005-06-23 | — | — | US | claimed |
| EP-1524266-A1 | Pharmaceutical composition | GLAXO GROUP LIMITED (GB) | 2005-04-20 | — | — | EP | claimed |
| WO-2004091616-A1 | COMBINATIONS OF PAROXETINE AND 4- (S) - (4-ACETYL-PIPERAZIN-1-YL) -2- (R)- (4-FLUORO-2-METHYL-PHENYL -PIPERIDINE-1-CARBOXYLIC ACID [1- (R) -(3,5-BIS-TRIFLUOROMETHYL-PHENYL) -ETHYL] METHYLAMIDE FOR TREATMENT OF DEPRESSION AND / OR ANXIETY | GLAXO GROUP LIMITED (GB) | 2004-10-28 | — | — | WO | claimed |
| EP-1326832-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-10-06 | — | — | EP | claimed |
| CN-1483025-A | Chemical compounds | — | 2004-03-17 | — | — | CN | claimed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | claimed |
| EP-1326832-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-07-16 | — | — | EP | claimed |
| WO-2002032867-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021041-A1 | Chemical Compounds | OPRL1, OPRK1, OPRM1 | TACR1 53/4885CYP3A4 141/4885SIGMAR1 98/4885 |
| US-20050137208-A1 | Chemical compounds | TACR2, TAC3, MC2R | TACR1 5/4885CYP3A4 515/4885SIGMAR1 328/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | TACR1 188/4885CYP3A4 148/4885SIGMAR1 434/4885 |
| US-20100081667-A1 | Chemical Compounds | OPRL1, OPRK1, OPRM1 | TACR1 53/4885CYP3A4 141/4885SIGMAR1 98/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | TACR1 7/4885CYP3A4 3349/4885SIGMAR1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.